Adaptimmune therapeutics plc ( afami-cel ) and our second generation mage-a4 cell therapy are promising candidates for the treatment of patients with cancer. we have taken decisive actions to pause, stop, and limit resources for non - core programs to concentrate our resources on these key priorities. we will undergo a reduction in headcount of between 25% and 30% between now and 317. these actions taken together will extend our cash runway into early 2025.